Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: A retrospective clinical study

Frontiers in Psychiatry

Psychiatry

Yujun Gao¹  Xianzhi Sun²  Xuebing Liu²  Lu Li²  Kuan Zeng²  Yi Li²  Jun Ma³ 

[1] Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China;Department of Psychiatry, Wuhan Mental Health Center, Wuhan, China;Wuhan Hospital for Psychotherapy, Wuhan, China;Department of Psychiatry, Wuhan Mental Health Center, Wuhan, China;Wuhan Hospital for Psychotherapy, Wuhan, China;Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China;

关键词: schizophrenia;    aripiprazole;    prolactin;    type 2 diabetes;    long-term hospitalized;    chronic;   

DOI  :  10.3389/fpsyt.2023.1124691

 received in 2022-12-15, accepted in 2023-01-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundOne of the most frequent side effects of atypical antipsychotics is hyperprolactinemia (HPRL), and metformin or aripiprazole co-prescription is regarded as an effective therapy option for reducing prolactin (PRL) levels. However, whether either of the two drugs can reduce PRL levels in patients with long-term hospitalized chronic schizophrenia with co-morbid type 2 diabetes (T2DM) has not been adequately reported.MethodsIn our study, long-term hospitalized chronic schizophrenia patients with co-T2DM who were prescribed olanzapine or risperidone as the primary antipsychotic medication were enrolled. A total of 197 of these cases with co-prescribed aripiprazole were set up as the study group (co-Ari group), and the other 204 cases without co-prescribed aripiprazole were set up as the control group (non-Ari group). The two groups’ variations in each target parameter were compared, and the variables affecting PRL levels were examined.ResultsCompared to the non-Ari group, fasting blood glucose (FBG), blood uric acid (UA), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels were significantly higher in the co-Ari group, but there was no difference in PRL levels. Co-prescribing aripiprazole had no impact on PRL levels in all patients with co-T2DM, and aripiprazole dose had no impact on PRL levels in the clinical subgroup of the co-Ari group.ConclusionAripiprazole not only worsened the severity of index disturbances associated to metabolism in long-term hospitalized chronic schizophrenia patients with co-T2DM on metformin-based hypoglycemic medications but also failed to lower PRL levels.

【 授权许可】

Unknown   
Copyright © 2023 Liu, Sun, Li, Zeng, Li, Gao and Ma.